The short answer
High-dose nicotinic acid can worsen glucose control. Have its formulation and dose reviewed during ertugliflozin treatment.
What this answer covers
Niacin supplements; high-dose nicotinic acid differs from nutritional intake, nicotinamide and niacin-containing combination drugs.
- Supplement or preparation
- Niacin
- Medication ingredient
- ertugliflozin
Why glucose may rise
High-dose nicotinic acid can worsen insulin resistance and increase glucose production. People taking diabetes medicines may need closer glucose checks when it is started or changed, even though ertugliflozin itself was not studied in the cited trial.
What the large trial found
Extended-release niacin combined with laropiprant caused more serious disturbances in diabetes control than placebo. This does not isolate niacin’s effects or determine an ertugliflozin-specific risk.
Identify the dose and form
A routine vitamin amount and a gram-dose lipid treatment are different exposures. Ask the pharmacist to distinguish nicotinic acid from nicotinamide and other formulations; do not add or increase diabetes medicine on your own.
Keep the prescribed medicine plan
Keep the prescribed ertugliflozin plan and tell the clinician about reduced intake, illness, vomiting or diarrhea. Do not change diabetes doses or fluid and salt advice to compensate for a supplement without review.
Review rising glucose readings
Report a sustained rise in glucose after starting or increasing nicotinic acid. The clinician can review the niacin indication and diabetes plan; do not assume that taking it at a different hour prevents this metabolic effect.
Evidence and practical considerations
Side effects & toxicity
A conditional high-dose nicotinic-acid glucose concern is supported by nutrient guidance and original outcome data, not an exact ertugliflozin interaction study. Increased blood glucose is distinct from hypoglycemia, ketoacidosis or impaired drug absorption.
- Exact scope
- Niacin supplements; high-dose nicotinic acid differs from nutritional intake, nicotinamide and niacin-containing combination drugs. with Exact ertugliflozin L-pyroglutamic acid single-ingredient oral tablets. Exact RxNorm IN1992672; STEGLATRO uses ertugliflozin L-pyroglutamic acid equivalent to the active ingredient. Metformin and sitagliptin combinations excluded.
- Medication form and route
- oral
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- No ertugliflozin-specific clinical event rate. Large trial used niacin with laropiprant; nutrient forms and doses are not interchangeable. No universal avoidance or interval.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed ertugliflozin.
Glucosuria, volume depletion, ketoacidosis precautions; hypoglycemia risk increases with insulin or insulin secretagogues. No routine sodium replacement instruction.
How this applies: Exact RxNorm IN1992672; STEGLATRO uses ertugliflozin L-pyroglutamic acid equivalent to the active ingredient. Metformin and sitagliptin combinations excluded.
No universal supplement dose, interval, event rate or untested formulation equivalence.
Source 2: Federal nutrient guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: People taking antidiabetes medicines and high-dose nicotinic acid.
Large nicotinic-acid doses can raise glucose; monitoring is advised during co-use with antidiabetes medicines.
How this applies: Only the original species, preparation, population and measured endpoint apply. No exact-pair clinical rate inferred.
General guidance does not quantify ertugliflozin-specific risk or establish a timing workaround.
Source 3: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 25,673 patients with vascular disease.
Active treatment increased serious disturbances in diabetes control.
How this applies: Only the original species, preparation, population and measured endpoint apply. No exact-pair clinical rate inferred.
Combination treatment; does not isolate niacin from laropiprant or establish a ertugliflozin-specific rate.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. |
Article revision: 8b6cb73103233808
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.